Altered Subsets and Activities of B Lymphocytes in Polycystic Ovary Syndrome
Na Xiao,Ke He,Fei Gong,Qi Xie,Jing Peng,Xian Su,Yeping Lu,Xuefeng Xia,Ge Lin,Lamei Cheng
DOI: https://doi.org/10.1016/j.jaci.2019.01.007
2019-01-01
Abstract:Polycystic ovary syndrome (PCOS) is a common endocrine disorder among women of reproductive age characterized by hyperandrogenism, polycystic ovarian morphology, and oligo-ovulation/anovulation.1Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop GroupRevised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).Hum Reprod. 2004; 19: 41-47Crossref PubMed Scopus (4588) Google Scholar Accumulating evidence suggests that PCOS is a chronic inflammatory and autoimmune disease. The ovaries of women with PCOS exhibit inflammation and fibrosis,1Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop GroupRevised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).Hum Reprod. 2004; 19: 41-47Crossref PubMed Scopus (4588) Google Scholar and the peripheral blood (PB) of women with PCOS has reduced numbers of anti-inflammatory regulatory T cells and increased serum levels of autoantibodies (eg, antihistone and anti–double-stranded DNA antibodies).2Hefler-Frischmuth K. Walch K. Huebl W. Baumuehlner K. Tempfer C. Hefler L. Serologic markers of autoimmunity in women with polycystic ovary syndrome.Fertil Steril. 2010; 93: 2291-2294Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar, 3Krishna M.B. Joseph A. Subramaniam A.G. Gupta A. Pillai S.M. Laloraya M. Reduced Tregs in peripheral blood of PCOS patients—a consequence of aberrant Il2 signaling.J Clin Endocrinol Metab. 2015; 100: 282-292Google Scholar Diabetes is also a chronic inflammatory and autoimmune disease. It has been reported that B cells play a critical role in the pathogenesis of diabetes.4Deng C. Xiang Y. Tan T. Ren Z. Cao C. Huang G. et al.Altered peripheral B-lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults.Diabetes Care. 2016; 39: 434-440Crossref PubMed Scopus (66) Google Scholar, 5Winer D.A. Winer S. Shen L. Wadia P.P. Yantha J. Paltser G. et al.B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies.Nat Med. 2011; 17: 610-617Crossref PubMed Scopus (713) Google Scholar Abnormal B lymphocytes promote insulin resistance through activation of proinflammatory T cells and production of pathologic antibodies.5Winer D.A. Winer S. Shen L. Wadia P.P. Yantha J. Paltser G. et al.B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies.Nat Med. 2011; 17: 610-617Crossref PubMed Scopus (713) Google Scholar However, little is known about the role of B cells in the development of PCOS. In this study we analyzed peripheral B cells in women with PCOS and found that the proportion and activity of CD19+ B cells were significantly increased. To determine whether CD19+ B cells contribute to the development of PCOS, we established a dehydroepiandrosterone (DHEA)–induced PCOS mouse model and found that PCOS did not develop after DHEA treatment in mice receiving CD19 antibody pretreatment. We recruited 63 women with PCOS diagnosed according to the 2003 Rotterdam criteria1Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop GroupRevised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).Hum Reprod. 2004; 19: 41-47Crossref PubMed Scopus (4588) Google Scholar and 41 healthy subjects (see the Methods section in this article's Online Repository at www.jacionline.org) aged 20 to 35 years. All participants provided informed consent. We isolated PBMCs and analyzed B-cell frequency and subsets using flow cytometry. The proportions and numbers of peripheral CD19+ B cells (8.95 ± 3.45 vs 7.09 ± 2.19 [P = .003] and 0.19 ± 0.10 vs 0.13 ± 0.06 [P = .005], respectively; Fig 1, A) and naive B cells (CD19+CD27− cells: 5.35 ± 2.76 vs 4.10 ± 1.69 [P = .011] and 1.11 ± 0.68 vs 0.77 ± 0.40 [P = .012], respectively; Fig 1, B) were greater in women with PCOS than in the control group. Naive B cells were an important source of precursors for pathologic autoantibody-secreting cells.6Duty J.A. Szodoray P. Zheng N.Y. Koelsch K.A. Zhang Q. Swiatkowski M. et al.Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors.J Exp Med. 2009; 206: 139-151Crossref PubMed Scopus (174) Google Scholar The percentages and numbers of memory B cells (CD19+CD27+CD38dim), plasmablasts (CD19+CD27+CD38hi), and regulatory B cells (CD19+CD24hiCD38hi) were not significantly different between control subjects and women with PCOS (data not shown). Levels of serum B-cell activating factor of the TNF family, which can promote the expansion and differentiation of B cells and the survival of autoreactive B cells,7Rawlings D.J. Metzler G. Wray-Dutra M. Jackson S.W. Altered B cell signalling in autoimmunity.Nat Rev Immunol. 2017; 17: 421-436Crossref PubMed Scopus (155) Google Scholar were greater in women with PCOS than in control subjects (P = .023; Fig 1, C), suggesting that B cells are activated in women with PCOS. Finally, we cultured PBMCs in vitro with CpG, CD40 ligand, and anti-human IgM/IgA/IgG (activator of the B-cell receptor) for 7 days. The results showed that B cells among PBMCs isolated from women with PCOS had a greater capacity for differentiating into plasmablasts (Fig 1, D) and produced high levels of IgG2 (P = .046; Fig 1, E) in vitro. Together, these data show that women with PCOS exhibited increases in the proportion and activity of CD19+ B cells. To determine whether CD19+ B cells contribute to the development of PCOS, we established a DHEA-induced PCOS mouse model (DHEA group)8Yuan X. Hu T. Zhao H. Huang Y. Ye R. Lin J. et al.Brown adipose tissue transplantation ameliorates polycystic ovary syndrome.Proc Natl Acad Sci U S A. 2016; 113: 2708-2713Crossref PubMed Scopus (107) Google Scholar and a CD19 antibody–pretreated mouse model (CD19 antibody plus DHEA group), which were treated with an antibody against CD19 before DHEA treatment. Mice receiving this antibody had approximately 95% reductions in the proportions of CD19+ B cells in PB and spleen samples relative to those receiving a control isotype (rat IgG2a) antibody (isotype plus DHEA group; see Fig E1, A, in this article's Online Repository at www.jacionline.org). Mice with PCOS had fewer corpus luteum, more cystic follicles, and higher body weights (Fig 2, A-C), which are consistent with changes in ovarian morphology and weight in women with PCOS. PCOS did not develop after DHEA treatment in the mice receiving CD19 antibody pretreatment, which had normal body weights and ovarian structures that were comparable with those in the control group (Fig 2, A-C). Mice receiving the isotype antibody had PCOS similar to the DHEA model group (Fig 2, A-C). Expression levels of fibrosis factors (collagen type III α 1 chain [Col3a1] and connective tissue growth factor [Ctgf]) were greater in the PCOS group than in the control group. Notably, CD19 antibody pretreatment attenuated or blocked these increases because expression levels of Col3a1 and Ctgf were lower than those in the DHEA and isotype groups (Fig 2, D). These data suggest that CD19 antibody pretreatment protected DHEA-treated mice from PCOS by inhibiting ovarian fibrosis. We next examined splenic B220+ B cells in DHEA-treated mice with and without CD19 antibody pretreatment. Flow cytometry and ELISA results showed that expression of the costimulatory molecule CD86 on splenic B220+ B cells, proportions of marginal zone B (MZB; CD21hiCD23lowB220+) and germinal center (GC; CD95+GL7+B220+) B cells, and serum levels of IgM increased with DHEA treatment, and this increase was blocked in mice receiving CD19 antibody (see Fig E1, B-E), indicating that CD19 antibody pretreatment inhibits B220+ B-cell activation induced by DHEA. It was reported that greater CD86 expression of B cells induced proinflammatory T-cell responses.9Jeannin P. Magistrelli G. Aubry J.P. Caron G. Gauchat J.F. Renno T. et al.Soluble CD86 is a costimulatory molecule for human T lymphocytes.Immunity. 2000; 13: 303-312Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar In this study we found that women with PCOS and DHEA-treated mice both had greater proportions of IFN-γ–expressing cells in CD3+ T cells relative to those in the control group (P = .038 and P = .019, respectively; see Fig E2 in this article's Online Repository at www.jacionline.org). In summary, we have identified a pathogenic role for CD19+ B cells in the development of PCOS. We propose a disease model in the development of PCOS: activation of CD19+ B cells leads to increases in proportions of MZB cells and GC formation and T-cell activation, which in turn result in increased autoantibody secretion and IFN-γ production. Finally, these changes lead to ovarian inflammation and fibrosis (see Fig E3 in this article's Online Repository at www.jacionline.org). In addition, we investigated the effect of CD19 antibody treatment in an established mouse model of PCOS. The preliminary results showed that CD19 antibody treatment can obviously recover ovarian structure, as characterized by cystic follicles decreases and corpus luteum increases (data not shown). Together, the results presented here suggest that CD19+ B cells might be a potential therapeutic target for PCOS. PCOS in mice was induced with DHEA (Sigma-Aldrich, St Louis, Mo), as previously described. Briefly, female prepuberal (21-day-old) C57BL/6 mice received daily subcutaneous injections of DHEA (6 mg/100 g body weight dissolved in 0.1 mL of sesame oil [Acros, Fisher Scientific, Waltham, Mass]) for 21 days. The control group received corresponding injections of 0.1 mL of sesame oil. Mice with CD19 antibody pretreatment and those given an isotype of the CD19 antibody received intraperitoneal injections of rat anti-mouse CD19 (200 μg; clone 1D3; Bio X Cell, West Lebanon, NH) or rat IgG2a (200 μg; clone 2A3; Bio X Cell) 48 hours before injection with DHEA. After 21 days of treatment, all mice were anesthetized and killed, and their blood, spleens, and ovaries were harvested. Spleens of mice were mechanically disrupted and filtered through 100-μm cell strainers to obtain single-cell suspensions. Ovaries were fixed in 4% formaldehyde, and sections were cut and stained with hematoxylin and eosin. All animal experiments were approved by the ethics review committee of Central South University. Patients and control subjects were recruited from the Reproductive & Genetic Hospital of CITIC-Xiangya. This study was approved by the Reproduction and Stem Cell Engineering Ethics Committee of Central South University, and all participants provided informed consent. Women with PCOS were diagnosed according to the 2003 Rotterdam criteria with at least 2 of the following features: oligo-ovulation or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovaries identified by means of ultrasonography (≥12 small follicles with diameters of 2–9 mm in at least 1 ovary and/or an ovary volume >10 mL). Patients with any other clinical conditions were excluded, such as nonclassic 21-hydroxylase deficiency, congenital adrenal hyperplasia, thyroid dysfunction, Cushing syndrome, or significant increases in serum prolactin levels. Healthy female control subjects were required to have (1) regular menstrual cycles (menstrual periods of 26–35 days) and no clinical manifestations of PCOS, (2) normal results from sex hormone and endocrine tests (exclusion of thyroid dysfunction or diabetes), (3) no ultrasonographic evidence of polycystic ovaries, (4) no evidence of systemic or inflammatory diseases, and (5) no receipt of hormonal (including oral contraceptives) or drug therapy in the last 3 months. Heparinized PB samples were collected from 63 women with PCOS and 41 healthy subjects aged 20 to 35 years. Full blood counts were obtained with an automated analyzer (XT-1800i; Sysmex, Kobe, Japan). PBMCs were isolated with standard Ficoll density gradient centrifugation techniques by using Lymphoprep (Tianjin Haoyang, Tianjin, China). Cells were incubated with antibodies purchased from BioLegend (San Diego, Calif) against human CD19–phycoerythrin (PE; clone HIB19), CD27–fluorescein isothiocyanate (FITC; clone M-T271), CD38-allophycocyanin (clone HI72), CD24-FITC (clone ML-5), CD3-FITC (clone OKT3), mouse CD3-FITC (clone 17A2), CD19-allophycocyanin (clone 6D5), B220–PE-Cy7 (clone RA3-6B2), CD21-PE (clone 7E9), CD23-FITC (clone B3B4), CD95-FITC (clone SA367H8), GL7-PE (clone GL7), and CD86-FITC (clone GL-1). To detect B-cell subpopulations in mice, we gated the lymphocytes defined by forward and side scatter and analyzed the expression of the B-cell markers CD19 and B220. Determinations of B-cell subpopulations were based on expression of major surface markers: naive B cells, CD19+CD27−; memory B cells, CD19+CD27+CD38dim; plasmablasts, CD19+CD27+CD38hi; GC B cells, CD95+GL7+B220+; and MZB cells, CD21hiCD23lowB220+. For intracellular IFN-γ staining, cells were cultured in the presence of phorbol 12-myristate 13-acetate (50 ng/mL; Sigma-Aldrich), ionomycin (1 μg/mL; Sigma-Aldrich), and monensin (BioLegend) for 5 hours. Cell-surface CD3 staining was performed first, and then cells were fixed, permeabilized with Cytofix/Cytoperm and Perm/Wash solutions (Becton Dickinson), and subsequently stained with mouse IFN-γ–PE (clone XMG1.2; BioLegend) or human IFN-γ-FITC (clone B27; BioLegend) antibodies. Data were acquired with a FACSAria I cytometer (Becton Dickinson, Franklin Lakes, NJ) and analyzed with FACSDiva software (BD Biosciences). PBMCs (1 × 106 cells per well) were cultured in RPMI supplemented with 10% FBS, 2.5 μg/mL F(ab')2 fragment goat anti-human IgA + IgG + IgM (Jackson ImmunoResearch, West Grove, Pa), 100 ng/mL CD40 ligand (Gibco, Grand Island, NY), 10 ng/mL IL-4 (Gibco), 10 ng/mL IL-10 (Gibco), 2.5 μg/mL CpG oligodeoxynucleotide 2006 (TCGTCGTTTTGTCGTTTTGTCGTT; Sangon Biotec, Shanghai), and 50 U/mL IL-2 (Gibco). After 7 days, supernatants and cells were collected for analysis. Serum samples were collected and stored at −80°C until analysis. Milliplex map assays (Millipore, Burlington, Mass) were used to quantitate serum levels of mouse immunoglobulin isotypes by using a Luminex 200 (Luminex, Auston, Tex), according to the manufacturer's instructions. Human serum B-cell activating factor of the TNF family levels were analyzed with ELISA kits (R&D Systems, Minneapolis, Minn). Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, Calif), and cDNA was synthesized (Invitrogen) according to the manufacturer's instructions. Quantitative PCR reactions were performed with SYBR Green Master (Roche, Mannheim, Germany) by using the Roche LightCycler 480 II system (Roche). The 18s gene was used as an endogenous control. All values are expressed as a fold increase or decrease relative to the expression of 18S. The primer sequences for genes were as follows: 18s forward primers, 5′-TTTGTTGGTTTTCGGAACTGA-3′ and 18s reverse primers, 5′-CGTTTATGGTCGGAACTACGA-3′; Ctgf forward primers, 5′-CATTAAGAAGGGCAAAAAGTGC-3′ and Ctgf reverse primers, 5′-CACACCCCACAGAACTTAGCC-3′; and Col3a1 forward primers, 5′-GGTCAGACCTGTGTGTTCCC-3′ and Col3a1 reverse primers, 5′-GGTCCATGTAGGCTACGCTG-3′. Data are presented as means ± SEMs. Statistical analyses were performed with SPSS 22.0 (SPSS, Chicago, Ill) and GraphPad Prism 5 (GraphPad Software, La Jolla, Calif) statistical software. The statistical significance of differences between 2 groups was determined by using 2-tailed unpaired Student t tests. Differences among multiple groups were compared by using 1-way ANOVA, followed by Newman-Keuls analysis. .Fig E2Increased numbers of T cells expressing IFN-γ in women and mice with PCOS. A, Quantification of percentages of IFN-γ–expressing cells gated on peripheral CD3+ T cells in women with PCOS (n = 6 [control subjects] and 11 [patients with PCOS]). B, Quantification of percentages of IFN-γ–expressing cells gated on splenic CD3+ T cells in mice with PCOS (n = 6 [control mice] and 8 [mice with PCOS]). *P < .05.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig E3Proposed role of B cells in development of PCOS. Treatment of mice with DHEA led to enhanced MZB cell expansion, GC formation, autoantibody production, and CD86 costimulatory molecule expression on splenic B cells. Simultaneously, CD86-expressing B cells and MZB cells contribute to T-cell activation and IFN-γ production. Together, autoantibody secretion and IFN-γ production result in ovarian inflammation and fibrosis.View Large Image Figure ViewerDownload Hi-res image Download (PPT)